128 related articles for article (PubMed ID: 24794695)
21. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
22. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes.
Skinner MA; Wells SA
Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335
[TBL] [Abstract][Full Text] [Related]
23. Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective.
Brauckhoff M; Machens A; Lorenz K; Bjøro T; Varhaug JE; Dralle H
Ann Surg; 2014 Apr; 259(4):800-6. PubMed ID: 23979292
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.
Robenshtok E; Tzvetov G; Grozinsky-Glasberg S; Shraga-Slutzky I; Weinstein R; Lazar L; Serov S; Singer J; Hirsch D; Shimon I; Benbassat C
Thyroid; 2011 Jan; 21(1):43-8. PubMed ID: 20954815
[TBL] [Abstract][Full Text] [Related]
25. [Role of markers in the diagnosis and follow-up of thyroid carcinomas].
Carmignani F; Piscopello L; Sammartini C
Chir Ital; 1994; 46(4):42-5. PubMed ID: 7882442
[TBL] [Abstract][Full Text] [Related]
26. [Multiple endocrine neoplasia type 2B].
Pijnenburg-Kleizen KJ; van Santen HM; Koolen DA; Claahsen-van der Grinten HL
Ned Tijdschr Geneeskd; 2015; 159():A7719. PubMed ID: 25944066
[TBL] [Abstract][Full Text] [Related]
27. [Multiple endocrine neoplasia type 2: familial variant of medullary carcinoma of the thyroid gland].
Neradilová M; Soutorová M; Vlcek P
Vnitr Lek; 1992 Sep; 38(9):850-9. PubMed ID: 1362306
[TBL] [Abstract][Full Text] [Related]
28. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
29. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A.
Lips CJ; Landsvater RM; Höppener JW; Geerdink RA; Blijham G; van Veen JM; van Gils AP; de Wit MJ; Zewald RA; Berends MJ
N Engl J Med; 1994 Sep; 331(13):828-35. PubMed ID: 7915822
[TBL] [Abstract][Full Text] [Related]
30. Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer.
Richards ML
Surg Oncol Clin N Am; 2009 Jan; 18(1):39-52, viii. PubMed ID: 19056041
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register.
Raue F; Kotzerke J; Reinwein D; Schröder S; Röher HD; Deckart H; Höfer R; Ritter M; Seif F; Buhr H
Clin Investig; 1993 Jan; 71(1):7-12. PubMed ID: 8095831
[TBL] [Abstract][Full Text] [Related]
32. Genetic aspects of familial thyroid cancer.
Morrison PJ; Atkinson AB
Oncologist; 2009 Jun; 14(6):571-7. PubMed ID: 19465682
[TBL] [Abstract][Full Text] [Related]
33. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
[TBL] [Abstract][Full Text] [Related]
34. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
35. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: An exploratory analysis.
Brauckhoff M; Machens A; Hess S; Lorenz K; Gimm O; Brauckhoff K; Sekulla C; Dralle H
Surgery; 2008 Dec; 144(6):1044-50; discussion 1050-3. PubMed ID: 19041016
[TBL] [Abstract][Full Text] [Related]
36. Comparison of sporadic and hereditary forms of medullary thyroid carcinoma.
Rosenberg-Bourgin M; Gardet P; de Sahb R; Schlumberger M; Caillou B; Guilloud-Bataille M; Travagli JP; Feingold N; Parmentier C
Henry Ford Hosp Med J; 1989; 37(3-4):141-3. PubMed ID: 2576948
[TBL] [Abstract][Full Text] [Related]
37. One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C?
Shifrin AL; Xenachis C; Fay A; Matulewicz TJ; Kuo YH; Vernick JJ
Surgery; 2009 Dec; 146(6):998-1005. PubMed ID: 19958926
[TBL] [Abstract][Full Text] [Related]
38. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).
Romei C; Cosci B; Renzini G; Bottici V; Molinaro E; Agate L; Passannanti P; Viola D; Biagini A; Basolo F; Ugolini C; Materazzi G; Pinchera A; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2011 Feb; 74(2):241-7. PubMed ID: 21054478
[TBL] [Abstract][Full Text] [Related]
39. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
[TBL] [Abstract][Full Text] [Related]
40. Current management of medullary thyroid cancer.
Sippel RS; Kunnimalaiyaan M; Chen H
Oncologist; 2008 May; 13(5):539-47. PubMed ID: 18515739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]